Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage. GNH USA supplies Nimotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts on the cerebrovascular system to reduce the risk of vasospasm after bleeding into the subarachnoid space. - Subarachnoid hemorrhage (post‑bleed): Prevention of cerebral vasospasm. - Aneurysmal SAH: Reduces risk of delayed cerebral ischemia. - Cerebral vasospasm: Improves cerebral blood flow after hemorrhage.

Nimodipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Flushing: warm sensation with reddening of skin. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare but serious cardiac event. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: potential hepatic involvement. - Thrombocytopenia: reduced platelet count. - Cardiac arrhythmias: irregular heart rhythms.

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for safety concerns. - Renal impairment: assess renal function and monitor fluid status. - Hepatic impairment: use with caution; monitor liver enzymes. - Hypotension: observe blood pressure closely during infusion. - Concomitant vasodilators: risk of additive blood pressure lowering. - Pregnancy: safety not established; weigh risks vs benefits. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other calcium channel blockers: additive cardiovascular depression. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations. - Nitrates: excessive hypotension risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: enhanced blood pressure lowering. - Diuretics: volume depletion may amplify hypotensive effect. - Other antihypertensives: monitor blood pressure and adjust therapy as needed.